GH1 and obstructive sleep apnea syndrome: Adenotonsillar hypertrophy can be associated with OSA, and newly diagnosed OSA has been documented in a subset of PWS subjects treated with GH from as early as 6 weeks to up to 2 years after starting therapy [47,48,49,50,51].